Filtered By:
Condition: Diabetes
Nutrition: Sodium

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 371 results found since Jan 2013.

SGLT2 inhibitors: Effect on myocardial infarction and stroke in type 2 diabetes
J Clin Endocrinol Metab. 2023 Feb 28:dgad113. doi: 10.1210/clinem/dgad113. Online ahead of print.ABSTRACTBACKGROUND: SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3P MACE), predominantly by reducing cardiovascular death. However reduction of the individual components, myocardial infarction (MI) or stroke (fatal and non-fatal) events have not been well explored.METHODS: In this meta-analysis, we included data avail...
Source: The Journal of Clinical Endocrinology and Metabolism - March 1, 2023 Category: Endocrinology Authors: Pradip Mukhopadhyay Debmalya Sanyal Purushottam Chatterjee Kaushik Pandit Sujoy Ghosh Source Type: research

Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis
Conclusions: In summary, this meta-analysis indicated that the use of SGLT2 inhibitors did not decrease the risk of stroke. And for some T2DM patients with high-risk factor of stroke, SGLT2 inhibitors therapy may be more suitable compared to some oGLD such as dipeptidyl peptidase-4 inhibitors. The results of this meta-analysis are necessary to be confirmed with further studies and clinical trials.Cerebrovasc Dis
Source: Cerebrovascular Diseases - January 31, 2022 Category: Neurology Source Type: research

Effect and Mechanism of Sodium Butyrate on Neuronal Recovery and Prognosis in Diabetic Stroke
This study examined the role of sodium butyrate in the prognosis of neurological function in diabetic stroke and the mechanism by which Tregs are amplified in the bilateral cerebral hemispheres. We evaluated the brain infarct volume, observed 48-h neuronal injury and 28-day behavioral changes, and calculated the 28-day survival rate in mice. We also measured Treg levels in peripheral blood and brain tissue, recorded changes in the blood ‒brain barrier and water channel proteins and neurotrophic changes in mice, measured cytokine levels and peripheral B-cell distribution in bilateral hemispheres and peripheral blood, and ...
Source: Journal of NeuroImmune Pharmacology - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
ConclusionsThe role of SGLT1/2 inhibition as an addition to GLP-1 RAs in patients with and without T2DM at increased risk for MI and stroke requires further study. Regardless, the finding that a relative increase in SGLT1/2 inhibition reduces the risk of MI and stroke as well as hospitalizations and urgent visits for heart failure could improve quality of life and reduce the healthcare burden associated with T2DM.
Source: Cardiovascular Drugs and Therapy - November 9, 2021 Category: Cardiology Source Type: research

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
ConclusionsBased on real-world data of type 2 diabetic patients in Hong Kong, SGLT2I use was associated with lower risk of incident AF, stroke/transient ischemic attack, and cardiovascular and all-cause mortality outcomes compared to DPP4I use.
Source: Cardiovascular Drugs and Therapy - February 10, 2022 Category: Cardiology Source Type: research

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
ConclusionsThe role of SGLT1/2 inhibition as an addition to GLP-1 RAs in patients with and without T2DM at increased risk for MI and stroke requires further study. Regardless, the finding that a relative increase in SGLT1/2 inhibition reduces the risk of MI and stroke as well as hospitalizations and urgent visits for heart failure could improve quality of life and reduce the healthcare burden associated with T2DM.
Source: Cardiovascular Drugs and Therapy - May 19, 2022 Category: Cardiology Source Type: research

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
ConclusionsBased on real-world data of type 2 diabetic patients in Hong Kong, SGLT2I use was associated with lower risk of incident AF, stroke/transient ischemic attack, and cardiovascular and all-cause mortality outcomes compared to DPP4I use.
Source: Cardiovascular Drugs and Therapy - May 29, 2023 Category: Cardiology Source Type: research

Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Diabetes Metab. 2023 Sep 5:101474. doi: 10.1016/j.diabet.2023.101474. Online ahead of print.ABSTRACTStroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present...
Source: Diabetes and Metabolism - September 7, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research

Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone?
The Insulin Resistance Intervention After Stroke (IRIS) trial has reported that treating insulin resistance with the peroxisome proliferator –activated receptor γ agonist pioglitazone hydrochloride reduced recurrent stroke or myocardial infarction (MI) by about one-fourth compared with placebo (pioglitazone, 9.0% vs placebo, 11.8%; hazard ratio [HR], 0.76; 95% CI, 0.62-0.93) in 3876 patients with recent (<6 months) ischemic stroke or transient ischemic attack and insulin resistance but without diabetes, heart failure, or bladder cancer. Pioglitazone was also associated with less incident diabetes vs placebo (3.8% vs ...
Source: JAMA Neurology - September 18, 2017 Category: Neurology Source Type: research

Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects on reducing hospitalization for heart failure and cardiovascular mortality, although the effect on atrial fibrillation (AF) has not been comprehensively investigated. Therefore, we performed a meta-analysis to assess the association between SGLT2 inhibitors and AF risk by systematically searching PubMed, Embase, and ClinicalTrials.gov. Two investigators independently identified randomized controlled trials, which compared SGLT2 inhibitors with control in patients with type 2 diabetes, heart failure, or chronic kidney disease. Prima...
Source: Journal of Cardiovascular Pharmacology - February 1, 2022 Category: Cardiology Tags: Review Article Source Type: research

B-po05-144 comparing sodium glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset atrial fibrillation and ischemic stroke
Given the susceptibility of patients with type 2 diabetes mellitus towards cerebrovascular complications, there is increasing research on the cerebrovascular-protective effects of novel anti-diabetic agents. However, few studies have compared sodium glucose cotransporter-2 inhibitor (SGLT2I) and dipeptidyl peptidase-4 inhibitor (DPP4I) in their effects on stroke and atrial fibrillation (AF).
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Sharen Lee, Jiandong Zhou, Xiansong Wang, Carlin Chang, Tong Liu, Dong Chang, Wing Tak Wong, William K.K. Wu, Bernard M.Y. Cheung, Gary Tse, Qingpeng Zhang Source Type: research

GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?
In Kim and colleagues' article [1] reporting a retrospective cohort study aiming to assess the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with type 2 diabetes mellitus (T2DM), one main conclusion is that GLP1RA tended to have more favorable ischemic outcomes. To some extent, this conclusion is exaggerated because GLP1RA and SGLT2i had the similar risks of coronary revascularization and stroke according to the main results of this article.
Source: International Journal of Cardiology - July 12, 2022 Category: Cardiology Authors: Lixin Du, Yu Zhang, Pan Wang, Zhigang Li, Yunhui Zhao, Jianpeng Yuan Tags: Letter to the Editor Source Type: research